New research finds MS patients had strong T-cell activation in response to COVID-19 vaccination

Aug. 9, 2022
Study from the Tisch Multiple Sclerosis Research Center of New York shows importance of analyzing T-cell response in COVID vaccines, particularly for immunocompromised individuals.

New research, published in Frontiers in Immunology and conducted by the Tisch Multiple Sclerosis Research Center of New York, has found that multiple sclerosis (MS) patients receiving anti-CD20 therapy saw strong T-cell activation after receiving two doses of the COVID-19 vaccine.

Anti-CD20 therapies cause B-cell depletion, and MS patients receiving these therapies are considered especially vulnerable to COVID-19 due to their lower production of antibodies. This research advances the analysis of T-cell responses, particularly for MS patients, and underscores the larger need to better understand T-cell responses among immunocompromised individuals. Further research advancements may have potential implications for future vaccine designs and applications.

In a group of 43 MS patients receiving anti-CD20 therapy, the study analyzed the humoral and cellular responses to mRNA COVID-19 vaccines during the first six months after receiving the vaccines. Their responses were compared to those of a healthy control cohort of 34 individuals. After receiving both vaccine doses, MS patients saw a seroconversion rate, measuring the development of antibodies in the blood serum, of only 23.8%.

However, the study found strong T-cell activation across MS patients, with no difference in T-cell response regardless of the patient’s form of MS (relapsing remitting versus progressive MS), anti-CD20 therapy administered (Rituximab versus Ocrelizumab), and the type of mRNA-based vaccine received (Pfizer versus Moderna).

Additionally, even with subjects who had severe B-cell depletion and failed seroconversion, the study found significantly higher SARS-CoV-2 spike-specific T-cell cytokine release and strong T-cell proliferation capacity compared to controls. Consequently, the study’s findings suggest that the vaccine may generate a partially adaptive immune response, driven by a functionally competent T-cell arm, in MS patients with B-cell depletion.

Read the full release on Businesswire

matawee matipano/iStock/Getty Images Plus/Getty Images
gettyimages1176254834
ID 335772838 © Yulia Ryabokon | Dreamstime.com
dreamstime_xxl_335772838
ID 3961118 © Sebastian Czapnik | Dreamstime.com
dreamstime_xxl_3961118
ID 12187971 © Valentyn75 | Dreamstime.com
dreamstime_xxl_12187971